ARO-INHBE

PreclinicalSmall molecule

Arrowhead Pharmaceuticals

ARO-INHBE is one of 72 small molecule programs targeting Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

ObesityRecruiting

Diabetes MellitusPhase 1/Phase 2

Active, not recruiting

ObesityPreclinical

Recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

2 2

Avapro

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

—4

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Preclinical

—8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Cetrotide

EMD Serono

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Obesity

NCT06700538

Clinical

Trials by Indication[1]

Obesity1 trial

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Preclinical·NCT06700538·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARO-INHBE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-INHBE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-INHBE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Arrowhead Pharmaceuticals

ARO-INHBE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Obesity1 trial

References

Drug Info

Quick Facts

Related News